Member Info for BuenaVista

Avacta holds a lottery before every published item and the lucky winner gets to introduce a deliberate mistake. Posters, abstracts and RNSes aren't too big an issue but the patents and submissions to regulatory authorities can be a bit dicey.

Actually a large part of Novartis' recent infusion of cash came from its sale of Roche shares:

Prompt: How much did Novartis get from selling its Roche holding?

ChatGPT: In November 2021, Novartis sold its entire stake in Roche, amounting to approximately 33% of the voting shares, for $20.7 billion. Novartis had held the Roche shares for nearly two decades, and the sale was part of Novartis’ strategy to streamline its operations and focus on innovative medicines​ {GlobeNewswire}{Novartis}. The proceeds from this sale were intended to support Novartis' capital allocation priorities, including strategic business investments, share buybacks, and dividends​ {Novartis}.

Can we see the IPO coming over the horizon yet???!

So excited about the IPO! WooHoooo! But until we get news of the IPO, here's a tidbit...

"They [Novartis] lost out in a few transactions incl. Point Biopharma to Lilly"

Prompt: Did Novartis want to buy Point Biopharma?

ChatGPT: No, it wasn't Novartis, but Eli Lilly that pursued Point Biopharma. In October 2023, Lilly announced its plan to acquire Point Biopharma, a company focused on radiopharmaceutical therapies, for $1.4 billion. The deal was part of Lilly’s strategy to expand into the radiopharmaceutical space, particularly targeting cancer treatments using radioligand therapies. Point Biopharma specializes in manufacturing these therapies in-house, which was seen as a valuable asset for Lilly's growing oncology portfolio. Novartis, on the other hand, has also been active in the radiopharmaceutical sector, but it pursued different acquisitions, such as Mariana Oncology, as part of its own expansion in cancer treatments​ {pharmaphorum}{BioPharma Dive)(MedCity News}.

Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition: https://medcitynews.com/2024/05/novartis-acquisition-mariana-oncology-radiopharmaceuticals-lung-cancer/

"Novartis’s two commercialized radiopharmaceuticals are from acquisitions: Lutathera came in 2017 followed by Pluvicto in 2018. The Swiss pharma giant’s purchase of Mariana continues a newer streak of radiopharmaceuticals dealmaking by other big pharma layers. Last year, Eli Lilly entered the radiopharmaceuticals space with the $1.4 billion acquisition of Point Biopharma. Bristol Myers Squibb soon followed with its $4.1 billion acquisition of RayzeBio. In March, AstraZeneca agreed to pay $2 billion to buy partner Fusion Pharmaceuticals."

Are you logged in?

HurstBot means the IPO. Due any day now. Could be today! Bagels all round and strong cawfee at the ready for the late night reading through of the IPO, praise be.

Well the technical term is 'fecking amazing', if that helps.

Glad I've got a bit of cash on the sidelines ready to take advantage of today's inevitable good news share price drop.🥴

Bad luck guys. HurstBot has plagued the Avacta board these past couple of years spouting its tripe and always with a 'Strong Buy'. Best ignored or binned.

As you only post to knock the company and are clearly not invested, it is you, matey, who should be excluded. Enjoy the green bin.

What is this "we" that you speak of?

If Avacta were to do that, then we'd get an RNS such as this for the two posters at EORTC in Barcelona tomorrow, 24th:

https://www.lse.co.uk/rns/AVCT/avacta-unveils-pipeline-expansion-at-eortc-2024-huquyksayaxi6wi.html

So where are your sources for these others you list?

There may be more candidates in the pipeline, but for licensing out rather than display on the website (until they are licensed out.)

It's three months until the next repayment is due. Probably best not to count chickens before they hatch, despite the encouraging sounds coming from inside, and to pay in shares until cash from a deal is firmly in the bank. In the meantime the share price will no doubt continue to meander.

@ShearClass, it was mentioned in the interims RNS on 30 September.

"The Board of Directors is also exploring opportunities for a dual listing on NASDAQ and an update on this aspect of the Group's longer-term financing strategy will be provided in due course"

ESMO data: https://avacta.com/esmo-poster-data-video-presentation-by-chris-coughlin/ see Case Study 1 from 15:20.

This patient had a partial resonse of ~45% (see waterfall chart at 13:30) but discontinued treatment because he (a 79 year old so would never be given straight Dox for his salivary gland cancer, where Dox is the treatment) had reached the lifetime max doxorubicin exposure.

So you're full of BS.

I'll say it again. The data collected and presented so far is from safety and tolerability studies, NOT an efficacy study.

I'd rather have the cash invested in the Tempus collaboration than splashed out on repaying the loan.

@blackcap, why do you say tumours stopped responding? Why do say tumours presumably continued to grow? What is your evidence for these statements? It is a false assumption to say that the best observed responses were not the latest measurements. In any case, treatment may have ceased for several reasons, including reaching maximum lifetime anthracyclin dose. In every case, these are stage 4 patients who've had multiple lines of treatment, which is fine for demonstrating safety and tolerability but not the type of patients that would be chosen for a study of efficacy.

The FAPi PET scans were not, as you say, taken over time. They were initial scans to determine the level of FAP present and hence suitability of the patient to join the trial. (Today's announced AI approach is a more convenient, cheaper and scalable way to achieve this.)

From your contributions on this board you don't seem to be invested or even interested in seeing Avacta succeed.

Cancer is a non-communicable disease so resistance does not transfer from person to person in the way that infectious diseases or immunity to pathogens might. Resistance has to develop within each individual.

Are you investigating genetic typing (e.g. using AI) to determine which cancers are likely to be best treated with pre|CISION drugs and which side effects are likely for which patients?

We have designed a very data rich Phase 1 study that will measure a number of exploratory biomarkers. These data will be presented in 2024 when new intellectual property has been protected.

- - - - -

I wonder what and where that new IP is.